Qunling Zhang

1.6k total citations
51 papers, 972 citations indexed

About

Qunling Zhang is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Qunling Zhang has authored 51 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 23 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Qunling Zhang's work include Lymphoma Diagnosis and Treatment (26 papers), Viral-associated cancers and disorders (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Qunling Zhang is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Viral-associated cancers and disorders (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Qunling Zhang collaborates with scholars based in China, United States and France. Qunling Zhang's co-authors include Jian Zhang, Xichun Hu, Biyun Wang, Si Sun, Juan Gu, Minhao Fan, Ye Guo, Kai Xue, Francisco J. Hernandez‐Ilizaliturri and Cory Mavis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Qunling Zhang

48 papers receiving 963 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qunling Zhang China 15 482 390 226 189 164 51 972
Leah M. Cook United States 17 496 1.0× 355 0.9× 156 0.7× 190 1.0× 74 0.5× 35 1.0k
Beverly L. Falcón United States 16 804 1.7× 435 1.1× 216 1.0× 339 1.8× 126 0.8× 34 1.4k
Guido Giordano Italy 16 267 0.6× 493 1.3× 179 0.8× 225 1.2× 79 0.5× 76 916
Ricardo Costa Brazil 16 504 1.0× 403 1.0× 211 0.9× 299 1.6× 98 0.6× 17 1.1k
Yiyan Lei China 20 434 0.9× 318 0.8× 203 0.9× 244 1.3× 102 0.6× 70 1.0k
Timothy McDonnell United States 12 343 0.7× 406 1.0× 157 0.7× 219 1.2× 186 1.1× 19 866
Graham H.P. Richmond United Kingdom 5 492 1.0× 473 1.2× 321 1.4× 175 0.9× 63 0.4× 6 947
Teresa Di Desidero Italy 24 421 0.9× 542 1.4× 253 1.1× 200 1.1× 91 0.6× 52 1.1k
Nam Y. Lee United States 23 832 1.7× 284 0.7× 141 0.6× 234 1.2× 45 0.3× 45 1.2k
Timothy G. Whitsett United States 18 527 1.1× 247 0.6× 239 1.1× 266 1.4× 113 0.7× 35 996

Countries citing papers authored by Qunling Zhang

Since Specialization
Citations

This map shows the geographic impact of Qunling Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qunling Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qunling Zhang more than expected).

Fields of papers citing papers by Qunling Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qunling Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qunling Zhang. The network helps show where Qunling Zhang may publish in the future.

Co-authorship network of co-authors of Qunling Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Qunling Zhang. A scholar is included among the top collaborators of Qunling Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qunling Zhang. Qunling Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Guangliang, Qunling Zhang, Ran Li, et al.. (2024). Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study. Cancer Medicine. 13(16). e70142–e70142. 3 indexed citations
2.
Wu, Yonghe, Baohua Yu, Qunling Zhang, et al.. (2024). PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Blood Research. 59(1). 36–36. 2 indexed citations
3.
Huang, Yao‐Hui, Yuran Qiu, Qunling Zhang, et al.. (2024). Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Reports Medicine. 5(2). 101416–101416. 8 indexed citations
4.
Ji, Dongmei, Shiyu Jiang, Qunling Zhang, et al.. (2023). Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor. Clinical and Translational Science. 16(8). 1396–1407. 1 indexed citations
5.
Qiu, Shi, Yizhen Liu, Zuguang Xia, et al.. (2022). Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. Journal of Cancer. 13(3). 998–1004. 4 indexed citations
6.
Sun, Qi, Aihua Zou, Shun Zhu, et al.. (2022). Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage. Annals of Translational Medicine. 10(10). 570–570. 3 indexed citations
7.
Ji, Dongmei, Zuguang Xia, Kai Xue, et al.. (2022). Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. BMC Cancer. 22(1). 403–403. 2 indexed citations
8.
Sun, Qi, Ying Ye, Xiaoting Sun, et al.. (2022). MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma. Cancer Letters. 537. 215678–215678. 12 indexed citations
9.
Singh, Anil, Juan Gu, Qunling Zhang, et al.. (2020). Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma. SHILAP Revista de lepidopterología. 8(1). 10–10. 25 indexed citations
10.
Zhang, Man, Huai Yang, Lu Wang, et al.. (2019). An interactive nomogram to predict healthcare-associated infections in ICU patients: A multicenter study in GuiZhou Province, China. PLoS ONE. 14(7). e0219456–e0219456. 2 indexed citations
11.
Shi, Jing, Ye Guo, Chujie Zhang, et al.. (2017). Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy. International journal of cardiac imaging. 33(6). 857–868. 32 indexed citations
12.
13.
Xue, Kai, Juan Gu, Qunling Zhang, et al.. (2015). Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Journal of Cancer Research and Clinical Oncology. 142(2). 379–387. 73 indexed citations
14.
Li, Ting, Qunling Zhang, Jian Zhang, et al.. (2014). Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer. 14(1). 96–96. 66 indexed citations
15.
Lu, Ying, Bing Chen, Tao Zhen, et al.. (2013). Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells. Proceedings of the National Academy of Sciences. 110(6). 2258–2263. 70 indexed citations
16.
Cao, Bing, Xiaoyan Zhou, Dongmei Ji, et al.. (2012). Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab. Oncology Letters. 4(3). 541–545. 3 indexed citations
17.
Wang, Leiping, Qunling Zhang, Jian Zhang, et al.. (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 11(1). 248–248. 109 indexed citations
18.
Zhao, Xinmin, Xiaofeng Xu, Qunling Zhang, et al.. (2011). Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer. 11(1). 403–403. 16 indexed citations
19.
Zhang, Qunling, et al.. (2009). [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].. PubMed. 17(5). 1215–9. 2 indexed citations
20.
Zhao, Weili, Yanyan Liu, Qunling Zhang, et al.. (2008). PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood. 111(7). 3867–3871. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leah M. Cook Breakdown of academic impact, for papers by Beverly L. Falcón Breakdown of academic impact, for papers by Guido Giordano Breakdown of academic impact, for papers by Ricardo Costa Breakdown of academic impact, for papers by Yiyan Lei Breakdown of academic impact, for papers by Timothy McDonnell Breakdown of academic impact, for papers by Graham H.P. Richmond Breakdown of academic impact, for papers by Teresa Di Desidero Breakdown of academic impact, for papers by Nam Y. Lee Breakdown of academic impact, for papers by Timothy G. Whitsett
Rankless by CCL
2026